Vivani Medical Reports Positive Preclinical Data for Once-Yearly Semaglutide Implant NPM-139

Vivani Medical, Inc.

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration in healthy rats over 91 days.
Data show smooth, non-fluctuating in vivo release and continuous semaglutide exposure, supporting potential for once or twice-yearly dosing.
Vivani's proprietary NanoPortal technology demonstrated versatility beyond exenatide implant NPM-115, with in vitro stability over one year.
First-in-human study LIBERATE-1 for NPM-115 remains on track for top-line data by mid-2025, providing critical information for NPM-139.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.